



# Evorel Conti and Evorel Sequi – risk of dispensing error

**E**vorel Conti and Evorel Sequi HRT patches have similar names and contain the same ingredients in the same strength. However, Evorel Conti provides progestogen every day, and Evorel Sequi provides sequential progestogen, in the second 14 days for each cycle.

Given the similarity in names, there is a risk of dispensing error occurring, and so it is important to understand the difference.

## Evorel Conti – continuous combined HRT

Evorel Conti transdermal patches are licenced by the HPRA. The full SPC name is Evorel Conti 50/170 micrograms per 24 hours Transdermal Patch.

Each Evorel Conti transdermal patch releases 50 micrograms estradiol and 170 micrograms norethisterone acetate over 24 hours.

Evorel Conti transdermal patches contain 8 patches in each box, and every patch is the same. They all contain estradiol and norethisterone. Evorel Conti is a *continuous combined HRT* which involves

taking estradiol and progestogen every day *without a break*.

Evorel Conti is licenced in Ireland and indicated for Hormone Replacement Therapy (HRT) for the relief of menopausal symptoms in post-menopausal women more than six months post-menopause.

## Evorel Sequi – continuous sequential HRT

Evorel Sequi transdermal patches have not been licenced in Ireland since 2003 but are available as an unlicenced medicine from the UK. Each box of Evorel Sequi patches also contains 8 patches – but contain 4 x Evorel 50 microgram patches containing only estradiol and 4 x Evorel Conti patches containing estradiol and norethisterone.

Evorel Sequi is a *continuous sequential HRT preparation*.

A treatment cycle with Evorel Sequi is 28 days and patches should be changed twice a week. During the first 14 days, one estradiol-only (Evorel 50) patch is worn without interruption. During days 15-28, one estradiol

+ norethisterone (Evorel Conti) patch is worn without interruption.

Continuous sequential HRT, also called cyclical HRT, is often recommended for women taking combined HRT who have menopausal symptoms but still have their periods.

Evorel Sequi is licenced and indicated in the UK for:

- Hormone Replacement Therapy for oestrogen deficiency symptoms in peri- and post-menopausal women; and
- Prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are intolerant of or contraindicated for other medicines used in the prevention of osteoporosis.

